newsfilter
← Latest News
GlobeNewswire·

AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting

Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib Latest analysis of Phase 2 study show tivozanib demons